

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

02 Jun 2026

### Effect of N-acetyl cysteine supplementation versus placebo on clinical outcomes in women with chronic pelvic pain syndrome: a double-blind randomized clinical trial

#### Protocol summary

##### Study aim

To assess the effect of N-acetyl cysteine supplementation versus placebo on clinical outcomes in women with chronic pelvic pain syndrome

##### Design

This is a double-blind randomized clinical trial, in which 60 eligible patients will be randomly assigned to the intervention and control groups

##### Settings and conduct

The eligible women with chronic pelvic pain syndrome referring to the Shahid Beheshti Hospital in Hamadan city during the study period will be enrolled in the trial and will be randomly assigned to the intervention and control groups through the block randomization. This trial will be double-blinded so that neither patients nor the physician examining the patients will be aware of the intervention.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Age of 18 to 50 years, Women with chronic pelvic pain syndrome for at least 6 months, Exclusion criteria: Presence of pathologic or infamous reason for chronic pelvic pain, Mild symptoms (the score less than 15 based on NIH-CPSI questionnaire), Chronic liver or renal disease, Kidney stone or urogenital tract infection, History of surgery of urogenital tract, Contraindication of N-acetyl cysteine

##### Intervention groups

Intervention group: Amitriptyline 25 mg daily plus N-acetylcysteine tablets (manufactured by Osweh Pharmaceutical Co., Tehran, Iran) 600 mg every 12 hours for 2 months Control group: Amitriptyline 25 mg daily plus placebo tablets (manufactured by Shahid Beheshti School of Pharmacy) every 12 hours for 2 months

##### Main outcome variables

Primary outcome: Clinical symptoms

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20120215009014N376**

Registration date: **2021-01-22, 1399/11/03**

Registration timing: **prospective**

Last update: **2021-01-22, 1399/11/03**

Update count: **0**

##### Registration date

2021-01-22, 1399/11/03

##### Registrant information

##### Name

Jalal Poorolajal

##### Name of organization / entity

Department of Epidemiology & Biostatistics Hamadan University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 81 1838 0090

##### Email address

poorolajal@umsha.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-04-21, 1400/02/01

##### Expected recruitment end date

2021-11-21, 1400/08/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Effect of N-acetyl cysteine supplementation versus placebo on clinical outcomes in women with chronic pelvic pain syndrome: a double-blind randomized clinical trial

**Public title**

Effect of N-acetyl cysteine supplementation versus placebo on clinical outcomes in women with chronic pelvic pain syndrome

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Age of 18 to 50 years, Women with chronic pelvic pain syndrome for at least 6 months,

**Exclusion criteria:**

Presence of pathologic or infamous reason for chronic pelvic pain, Mild symptoms (the score less than 15 based on NIH-CPSI questionnaire), Chronic liver or renal disease, Kidney stone or urogenital tract infection, History of surgery of urogenital tract, Contraindication of N-acetyl cysteine

**Age**

From **18 years** old to **50 years** old

**Gender**

Female

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

The patients will be randomly assigned to intervention and control groups using block randomization. For this purpose, we will prepare four sheets of paper, writing on two sheets the name of the intervention and on the other two sheets the name of the control. The paper sheets will be pooled, placed in a container, and randomly drawn one at a time for each patient without replacement until all four sheets are drawn. The four paper sheets will be then placed back into the container, and this action repeated until the sample size is reached.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

The shape of the medications and placebos will be perfectly the same. Therefore, patients will be unaware of the type of intervention. The physician who will examine the patients will not be aware of the intervention. Thus, the trial will be run as triple-blind

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Hamadan University of Medical Sciences

**Street address**

Vice-chancellor for Research and Technology, Hamadan University of Medical Sciences, Shahid Fahmideh Ave

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Approval date**

2020-10-24, 1399/08/03

**Ethics committee reference number**

IR.UMSHA.REC.1399.629

**Health conditions studied****1****Description of health condition studied**

Chronic pelvic pain syndrome

**ICD-10 code**

R10.2

**ICD-10 code description**

Pelvic and perineal pain

**Primary outcomes****1****Description**

Clinical symptoms

**Timepoint**

Before the intervention and 4 and 8 weeks after that

**Method of measurement**

Using the National Institutes of Health - Chronic Prostatitis Symptom Index (NIH-CPSI) standard questionnaire

**Secondary outcomes**

empty

## Intervention groups

### 1

#### Description

Intervention group: Amitriptyline 25 mg daily plus N-acetyl cysteine tablets (manufactured by Osweh Pharmaceutical Co., Tehran, Iran) 600 mg every 12 hours for 2 months

#### Category

Treatment - Drugs

### 2

#### Description

Control group: Amitriptyline 25 mg daily plus placebo tablets (manufactured by Shahid Beheshti School of Pharmacy) every 12 hours for 2 months

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Shahid Beheshti Hospital in Hamadan city

##### Full name of responsible person

Somayeh Rahymy

##### Street address

Shahid Beheshti Hospital, Eram Ave.

##### City

Hamadan

##### Province

Hamadan

##### Postal code

6517838695

##### Phone

+98 81 3838 0283

##### Email

rhymy2958@gmail.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Hamedan University of Medical Sciences

##### Full name of responsible person

Dr. Saeid Bashirian

##### Street address

Hamadan University of Medical Sciences, Shahid Fahmideh Ave

##### City

Hamadan

##### Province

Hamadan

##### Postal code

6517838695

##### Phone

+98 81 3838 0717

##### Email

info.research@umsha.ac.ir

##### Grant name

##### Grant code / Reference number

##### Is the source of funding the same sponsor organization/entity?

Yes

##### Title of funding source

Hamedan University of Medical Sciences

##### Proportion provided by this source

100

##### Public or private sector

Public

##### Domestic or foreign origin

Domestic

##### Category of foreign source of funding

empty

##### Country of origin

##### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Hamedan University of Medical Sciences

##### Full name of responsible person

Somayeh Rahymy

##### Position

Medical Student

##### Latest degree

Medical doctor

##### Other areas of specialty/work

Medical Genetics

##### Street address

School of Pharmacy, Hamadan University of Medical Sciences, Shahid Fahmideh Ave.

##### City

Hamadan

##### Province

Hamadan

##### Postal code

6517838695

##### Phone

+98 81 3838 0572

##### Email

rhymy2958@gmail.com

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

Hamedan University of Medical Sciences

##### Full name of responsible person

Dr. Maryam Mehrpooya

##### Position

Pharmacologist

##### Latest degree

Ph.D.

##### Other areas of specialty/work

Medical Pharmacy

**Street address**

School of Pharmacy, Hamadan University of Medical Sciences, Shahid Fahmideh Ave.

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3838 0572

**Email**

m\_mehrpooya2003@yahoo.com

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Dr. Jalal Poorolajal

**Position**

Professor of Epidemiology

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Epidemiology

**Street address**

School of Public Health, Hamadan University of Medical Sciences, Shahid Fahmideh Ave

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3838 0090

**Email**

poorolajal@umsha.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available